BRPI0618245A2 - composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica Download PDF

Info

Publication number
BRPI0618245A2
BRPI0618245A2 BRPI0618245-3A BRPI0618245A BRPI0618245A2 BR PI0618245 A2 BRPI0618245 A2 BR PI0618245A2 BR PI0618245 A BRPI0618245 A BR PI0618245A BR PI0618245 A2 BRPI0618245 A2 BR PI0618245A2
Authority
BR
Brazil
Prior art keywords
benzo
mmol
carboxylic acid
thiophene
pyrimidin
Prior art date
Application number
BRPI0618245-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0618245A2 publication Critical patent/BRPI0618245A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0618245-3A 2005-11-18 2006-11-15 composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica BRPI0618245A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
US60/738097 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
BRPI0618245A2 true BRPI0618245A2 (pt) 2011-08-23

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618245-3A BRPI0618245A2 (pt) 2005-11-18 2006-11-15 composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01143B (me) 2006-03-31 2013-03-20 Janssen Pharmaceutica Nv BENZOIMIDAZOL-2-IL PIRIMIDINI l PIRAZINI KAO MODULATORI HISTAMINSKOG H4 RECEPTORA
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
US8063212B2 (en) * 2006-12-21 2011-11-22 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
CN101563342B (zh) * 2006-12-21 2012-09-05 伊莱利利公司 用于治疗癌症的咪唑啉酮基氨基嘧啶化合物
PE20090803A1 (es) 2007-05-16 2009-07-11 Lilly Co Eli Compuestos triazolil aminopirimidin como inhibidores de plk1
MX2009012228A (es) 2007-05-16 2009-12-01 Lilly Co Eli Compuesto de triazolil aminopirimidina.
MX2011000080A (es) 2008-06-30 2011-03-02 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de pirimidina sustituidos.
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
KR20120059558A (ko) 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
MX2012012502A (es) 2010-04-27 2013-01-18 Hutchison Medipharma Ltd Compuestos pirimidinil indol.
US20140194383A1 (en) 2011-04-07 2014-07-10 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CA2864085C (en) 2012-02-08 2021-11-23 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
WO2018023070A1 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
MY199446A (en) 2016-07-29 2023-10-28 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) * 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法

Also Published As

Publication number Publication date
IL190489A0 (en) 2008-11-03
ZA200803940B (en) 2009-09-30
JP2009516697A (ja) 2009-04-23
NO20082594L (no) 2008-06-10
TNSN08227A1 (en) 2009-10-30
CN101309918A (zh) 2008-11-19
AR057911A1 (es) 2007-12-26
DE602006008187D1 (de) 2009-09-10
EA014426B1 (ru) 2010-12-30
US7547691B2 (en) 2009-06-16
ES2329085T3 (es) 2009-11-20
KR20080059451A (ko) 2008-06-27
PT1989200E (pt) 2009-10-12
DK1989200T3 (da) 2009-11-09
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
ATE437873T1 (de) 2009-08-15
AU2006337626A8 (en) 2008-06-19
MA30053B1 (fr) 2008-12-01
WO2007092095A3 (en) 2007-11-08
CR9947A (es) 2008-11-28
EP1989200A2 (en) 2008-11-12
TW200800201A (en) 2008-01-01
AU2006337626B2 (en) 2012-03-22
EP1989200B1 (en) 2009-07-29
WO2007092095A2 (en) 2007-08-16
EA200801362A1 (ru) 2009-02-27
KR100990771B1 (ko) 2010-10-29
US20080306082A1 (en) 2008-12-11
ECSP088456A (es) 2008-06-30
PE20070833A1 (es) 2007-08-27
CN101309918B (zh) 2010-12-29
PL1989200T3 (pl) 2009-12-31
SI1989200T1 (sl) 2009-12-31

Similar Documents

Publication Publication Date Title
BRPI0618245A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, formulação farmacêutica
EP2044051B1 (en) Pyridine and pyrazine derivatives as mnk kinase inhibitors
ES2527882T3 (es) Derivados de la 2-aminopirimidina y su uso médico
DK2552909T3 (en) 4-aminopyrimidine derivatives and their use as adenosine A 2A receptor antagonists
ES2328042T3 (es) Derivados de pirazol como unhibidores de los receptores tirosina cinasa.
KR102052670B1 (ko) 키나아제 저해제
ES2273047T3 (es) Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
CN1137100C (zh) 能够抑制表皮生长因子受体族之酪氨酸激酶的三环化合物
CN103958498B (zh) 作为lrrk2调节剂的氨基嘧啶衍生物
EP1966151A1 (en) Polycyclic indazole derivatives that are erk inhibitors
AU2007242594A1 (en) Pyrimidine derivatives as PI3K inhibitors
BR122014026094B1 (pt) compostos de fórmula ii, iii, iv e vi
CN110003219A (zh) 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
NZ546044A (en) Pyrimidothiophene compounds
CZ304059B6 (cs) Deriváty pyrimidinu a farmaceutický prostredek
BRPI0613452A2 (pt) derivados de 2,4-dianilino pirimidinas, o respectivo preparo, a tìtulo de medicamentos, composições farmacêuticas e notadamente como inibidores de ikk
BRPI0712898A2 (pt) indàis como moduladores de 5-ht6
CN101511824A (zh) 用于治疗糖原合酶激酶(gsk3)相关疾病的咪唑-嘧啶衍生物
ES2345257T3 (es) Tienopirazoles.
CN114105887B (zh) 一种氨基嘧啶衍生物及其制备方法和用途
TW201934546A (zh) 嘧啶類化合物、其製備方法及其醫藥用途
AU2009227111A1 (en) Novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof.
AU2011307220B2 (en) Phenylquinazoline derivatives
CN101479277A (zh) 作为pi3k抑制剂的嘧啶衍生物
AU2002217269A1 (en) Carbazole derivatives and their use as neuropeptide Y5 receptor ligands

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2280 DE 16/09/2014.